Cell therapy for moderate to severe lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy to calm the overactive immune system in people with lupus, which may reduce disease activity and improve daily living.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You must have a lupus diagnosis (according to international criteria).
- Your lupus must be moderate to severe and still active despite standard treatments.
- You must have tried at least one biologic medicine (like rituximab or belimumab) and other standard drugs.
- Your blood counts, liver, kidney, heart, and lung function must be within safe limits.
- You cannot be pregnant, nursing, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new cell therapy (RJMty19) for people with lupus that hasn't improved with standard treatments. It aims to reduce disease activity and may help those with active organ involvement.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Hear when a new Lupus Erythematosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.